Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222215 · ClinicalTrials.gov registry record · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Kristina A. Fanucci.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
- 1
- Study location
NCT07222215 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Kristina A. Fanucci. The registered enrollment target is 297 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07222215, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Kristina A. Fanucci.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medication in the class of therapy called CDK 4/6 inhibitors, including palbociclib, ribociclib, or abemaciclb. The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Capecitabine (a type of fluoropyrimidine antimetabolite)
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Elacestrant
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2030-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07222215
The ClinicalTrials.gov registry entry for NCT07222215 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Kristina A. Fanucci, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT07222215 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07222215 about?
NCT07222215 is a clinical study titled "PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)". The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medic...
What is the current status of trial NCT07222215?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2026-01-16. Estimated completion is 2030-10-01.
What conditions does trial NCT07222215 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Estrogen Receptor-positive Breast Cancer.
What interventions are being tested in trial NCT07222215?
The interventions under investigation include: Capecitabine (DRUG), Elacestrant (DRUG).
Who is sponsoring clinical trial NCT07222215?
This trial is sponsored by Kristina A. Fanucci, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222215 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.